NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Thursday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO stock opened at $4.20 on Thursday. The firm has a market cap of $8.45 million, a P/E ratio of -0.67 and a beta of 2.28. The firm’s fifty day moving average is $3.68 and its 200 day moving average is $3.85. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $5.68.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The business had revenue of $0.77 million for the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.